Small-cell lung cancer is usually highly sensitive to multidrug chemotherapy and radiotherapy (reviewed by Aisner et al., 1983; Greco et al., 1985; Livingston, 1986). Because the disease is known to metastasise early, many clinicians have adopted a treatment policy combining these two modalities in the initial treatment of patients, even when disease at presentation is apparently limited to the primary site and regional lymph nodes (MRC Lung Cancer Working Party, 1979). The role of radiotherapy to the tumour and related lymph nodes additional to chemotherapy remains uncertain: some series have shown that radiotherapy reduces the incidence of local recurrence and prolongs survival, but others suggest that chemotherapy alone gives as good results (reviewed by Bleehen, 1986) . The aims of treatment are to control the symptoms of disease and to prolong survival as assessed by median survival time or (more importantly) survival for 2 years or longer, or by local and metastatic relapse-free intervals.
Small-cell lung cancer is usually highly sensitive to multidrug chemotherapy and radiotherapy (reviewed by Aisner et al., 1983; Greco et al., 1985; Livingston, 1986) . Because the disease is known to metastasise early, many clinicians have adopted a treatment policy combining these two modalities in the initial treatment of patients, even when disease at presentation is apparently limited to the primary site and regional lymph nodes (MRC Lung Cancer Working Party, 1979) . The role of radiotherapy to the tumour and related lymph nodes additional to chemotherapy remains uncertain: some series have shown that radiotherapy reduces the incidence of local recurrence and prolongs survival, but others suggest that chemotherapy alone gives as good results (reviewed by Bleehen, 1986) . The aims of treatment are to control the symptoms of disease and to prolong survival as assessed by median survival time or (more importantly) survival for 2 years or longer, or by local and metastatic relapse-free intervals.
The treatment is troublesome to the patient and may be toxic and it is therefore undesirable to continue treatment for longer than is necessary. If the tumour responds, a maximum response, complete or partial (World Health Organization, 1979) , is usually achieved after only two or three courses of chemotherapy, but it is not known how much longer treatment should be continued to obtain maximum sustained therapeutic benefit (reviewed by Greco et al., 1985) . The present multicentre randomised study was designed to compare 12 against six courses of the same chemotherapy in the treatment of both limited and extensive disease, the patients with limited disease also receiving radiotherapy to the tumour and related lymph nodes after the second course of chemotherapy. Initial treatment (all patients) All patients were prescribed initial treatment with 6 courses of chemotherapy, each course given on three consecutive days at 3-week intervals. Etoposide 120mgm-2 was given by intravenous infusion over 30 min, together with cyclophosphamide 1 g m -2, methotrexate 35 mg m -2 and vincristine 1.3 mgm 2 (maximum dose 2.0 mg) by intravenous injection on day 1. Etoposide 240mg m-2 by mouth or 120 mg m-2 intravenously was given on days 2 and 3. Patients with limited disease were also given megavoltage radiotherapy to a midline dose of 40 Gy in 15 daily fractions over 3 weeks Br. J. Cancer (1989), 59, 584-590 between the second and third courses of chemotherapy, starting 3 weeks after the second course. It was delivered through planned portals to the primary site and mediastinal lymph nodes, the field extending at least from the suprasternal notch to 3 cm below the carina and encompassing the full width of the mediastinum and lung hila.
Allocation to maintenance or no maintenance chemotherapy Patients in partial or complete response (that is with an estimated decrease in tumour size of 50% or more (World Health Organization, 1979) ) at the time of the fifth course of initial chemotherapy were eligible for random allocation either to six more courses of maintenance chemotherapy (M series) or to no maintenance chemotherapy (NoM series), the allocation being stratified for admitting centre, extent of disease pretreatment and degree of response (partial or complete) at the time of randomisation. Maintenance chemotherapy consisted of the same chemotherapy in the same dosages as before, but starting 4 weeks after the sixth course of initial chemotherapy and at intervals of 4 instead of 3 weeks.
Reports and investigations In addition to a pretreatment report, a report on each patient was completed at each attendance for treatment, then monthly up to 12 months and then once every 3 months. These reports included details of the treatment given, the response to treatment, adverse reactions encountered, metastases, the blood haemoglobin concentration and total white cell and platelet counts. At death, the certified cause was reported and if an autopsy was done, the findings.
Assessment of quality of life At each attendance the clinician recorded his assessment of the patient's overall condition, level of activity and degree of breathlessness according to the categories shown in Table I . In addition, the patients themselves completed a daily diary card (Fayers & Jones, 1983 ) every evening after their last meal, recording how they had been feeling during the past 24h, coding their assessments as below. In all, 295 of the 497 patients completed the initial period of treatment and were still responding, and a further 29 completed but were no longer responding. The remaining 173 did not complete the initial period, the reason being death in 128, inadequate response in 16, refusal in 16 and toxicity in 13. Of the 295, 265 (53% of the 497) were allocated at random to either maintenance (131 patients) or no maintenance (134 patients) chemotherapy. The remaining 30 patients, all potentially eligible for randomisation, were not randomised, the reason being toxicity in 13, refusal in six and continuation of chemotherapy beyond six courses (without randomisation) in three; for the remaining eight no reason was given. Of the 265 patients allocated, 196 (74%) had had limited disease on admission and 99 (37%) had achieved a complete response as assessed at the time of randomisation.
Chemotherapy received During the initial period of treatment (Table II) , 278 (56%) of the 497 patients received their chemotherapy without modification. A further 156 (31%) had their chemotherapy modified at the decision of the clinician because of toxicity; 59 (12%) had all their chemotherapy stopped, and the remaining four (1%) never started chemotherapy: three died and the fourth declined all treatment.
Of the 131 patients allocated to receive maintenance chemotherapy, 46 (35%) received it without modification. A further 21 (16%) had their maintenance chemotherapy modified at the decision of the clinician because of toxicity, 31 (24%) had all their maintenance chemotherapy stopped and the remaining 33 (25%) never started maintenance chemotherapy: 18 decided not to continue, 12 began to relapse A proportional hazards model (Cox, 1972) Total patients 497 100 aPatients with haematological toxicity at routine assessments are shown. The figures in parentheses include patients with toxicity at all assessments, whether routine or not.
Adverse reactions
The main adverse reactions, other than alopecia, that were reported during the initial period of chemotherapy are shown in Table V . Haematological toxicity of WHO grade 2 (World Health Organization, 1979) or worse was reported at routine assessments immediately before a course of chemotherapy in 35% of patients. Additional blood counts were done, however, if there was concern about a patient's progress. When these additional results are included, haematological toxicity was reported in 45% of the patients. In addition, 17 (3%) patients had episodes of septicaemia attributed to drug-induced leucopenia and 98 (20%) were given blood transfusions for anaemia.
During the period after randomisation, adverse reactions were reported in 80 (61%) of the 131 M compared with 16 (12%/M) of the 134 NoM patients (P < 0.0001). In the M series, nausea without vomiting was reported in 45 (34%), vomiting in 40 (31%), paraesthesiae in 17 (13%), peripheral neuropathy in 10 (8%) and mouth ulcers in nine (7%). The corresponding results for the NoM series were four (3%), three (2%), none, two (1%) and one (1%). Septicaemia was reported in six of the M compared with one of the NoM patients. Thus, toxicity was considerably reduced by stopping chemotherapy after six courses.
There were 116 patients who received radiotherapy between the second and third courses of chemotherapy and who had their platelet counts measured at all five of the routine assessments before the first, second and third courses of chemotherapy and at the start and end of radiotherapy. Their platelet counts were compared (Table VI) with those of patients who did not receive radiotherapy but who had their platelet counts measured at all five of comparable routine assessments, namely before the first five courses of chemotherapy. The mean platelet counts were considerably reduced at the end of radiotherapy and 3 weeks afterwards but were unchanged at comparable assessments in the patients who did not receive radiotherapy. There were no equivalent differences attributable to radiotherapy in the white cell counts or haemoglobin concentrations (details not shown).
Quality of life
The findings on quality of life are to be reported and discussed in detail elsewhere. The main findings during the M/NoM comparison are summarised here.
Clinicians' assessments The overall condition of the patients, their level of physical activity and degree of breathlessness as recorded by the clinicians when the patients allocated to the M/NoM comparison attended for assessment at 3 weeks, 6 weeks, 3 months and 6 months from the date of randomisation are shown in Table VII . The proportions were similar for the two series initially, but by 6 months there was a clear advantage to the NoM patients, higher proportions being assigned the better categories and lower proportions the worse categories for all three assessments, namely overall condition (P < 0.05), level of physical activity (P < 0.01) and degree of breathlessness (P < 0.05).
Compliance in the use of the daily diary cards The intention was that diary cards should be completed daily by the patients from admission until approaching death. From the date of randomisation, 94 (35%) of the 265 patients returned no cards at all, 35 (13%) returned cards covering 1-25% of their survival time or of 6 months from randomisation (whichever was shorter), 31 (12%) 26-50% of this period and 105 (40%) 51-100%.
Quality of life as recorded by patients The quality of life during the 6-week period starting 3 weeks after the sixth course of chemotherapy as recorded by patients on their daily diary cards is expressed, in Table VIII 19  30  8  15  6  19  11  20   2   10  4  19  28  30  35  39  39  33  45  3  5  3  41  37  51  39  43  33  45  30  4  3  0  18  5  9  11  10  10 least 50% of the relevant data. The proportion of patientdays for the two best categories combined (categories 1 and 2) was higher for the NoM series for all five factors, and for the two worst categories combined (categories 4 and 5) was higher for the M series for all factors except mood. Thus, quality of life from the time of the M/NoM randomisation was better for the NoM patients, as assessed both intermittently by the clinicians and daily by the patients, further reason for not continuing chemotherapy beyond six courses.
Discussion
This study has shown that when the present chemotherapy regimen of etoposide, cyclophosphamide, methotrexate and vincristine is used in the treatment of limited or extensive small-cell lung cancer, no important overall therapeutic advantage is to be gained from a policy of continuing chemotherapy beyond six courses in patients still showing response at that time. Of 497 eligible patients admitted to the study, 265 completed their initial six courses of chemotherapy and were randomised to a further six courses of maintenance chemotherapy (131 patients) or to no further chemotherapy (134 patients) until relapse, the randomisation being stratified for admitting centre, extent of disease pretreatment and degree of response at the time of randomisation. In a straight comparison between the two groups of patients, there was no evidence of a difference in survival during 3 years of follow-up (P = 0.27, log rank test) and control of the primary cancer and of distant metastases was very similar. Of the 131 patients allocated to receive maintenance chemotherapy, only 35% received it without modification. A further 16% had it modified because of toxicity and 24% had it stopped; the remaining 25% never started. Nevertheless, there was no evidence of a trend between the duration of survival and the amount of maintenance chemotherapy actually received.
In analyses of subgroups of patients, there was a suggestion that maintenance chemotherapy may have prolonged survival among 99 patients with a complete response to their initial chemotherapy as assessed at the time of randomisation (P <0.05, log rank test). This finding should not, however, be regarded as conclusive, because comparing subgroups increases the likelihood of obtaining such a difference by chance (Simon, 1982) . Also, in the 91 patients (complete and partial responders) who were allocated to maintenance chemotherapy and who were still alive 6 months later, there was again no evidence of a trend between duration of survival and amount of maintenance chemotherapy actually received.
During the period of chemotherapy, deaths were not evenly distributed during and between courses. They were most likely to occur during the second week after the date of start of the last course before death, that is, when the white cell count was likely to have been at its lowest. This finding is similar to that observed by Souhami and his colleagues who also found that such deaths were more likely to occur in patients with other unfavourable prognostic factors present pretreatment, especially poor performance status, hepatomegaly, and abnormal liver function tests (Souhami et al., 1988) . In the present study, 26 of 32 assessable deaths during the first 3 weeks of the study occurred in patients with a poor performance status on admission (activity grade 3 or 4). Souhami and his colleagues (personal communication) have shown that this high risk of early death in patients with a poor performance status can be greatly reduced by giving antibiotics prophylactically during the early weeks of chemotherapy. In the present study such prophylaxis was left to the individual-clinician to decide.
Several drug schedules have been used in attempts to improve the results of therapy for small-cell lung cancer. They include alternating non-cross-resistant combinations, very high dose chemotherapy with autologous marrow rescue, regimens of alternating chemotherapy and radiotherapy, and maintenance chemotherapy after an initial induction course using either the same or different drugs (reviewed by Aisner et al., 1983; Greco et al., 1985; Livingston, 1986) . There is little if any evidence for any major improvement in survival as a result of these treatments compared with the more conventional ones, except in some small non-randomised studies.
The present study solely considers the duration of conventional treatment with the same combination chemotherapy throughout. Three other studies have addressed this same question. In a CALGB study of 258 patients (Maurer et al., 1980) , it was reported that maintenance chemotherapy significantly prolonged survival in patients with limited disease, with 33% of the patients alive at 24 months compared with 9% who did not receive maintenance chemotherapy. However, this was a complicated study which included three separate randomisations; one limb of the chemotherapy schedule was abandoned during the trial, and patients were randomised to the maintenance and no-maintenance series after achieving a complete response to six courses of induction chemotherapy. Only 46 patients with limited disease achieved a complete response and were eligible for randomisation. The results have also been questioned on the basis of whether the patients in fact received adequate induction therapy (Greco et al., 1985) .
In another study of 309 patients conducted by the Midland Small Cell Lung Cancer Group (Cullen et al., 1986) , 93 patients who achieved a complete or good response to induction chemotherapy with six courses of vincristine, doxorubicin and cyclophosphamide were randomised to a further eight courses of maintenance chemotherapy or to no further chemotherapy until relapse. Maintenance chemotherapy prolonged survival in the 61 patients with extensive disease on admission (P = 0.006, log rank test), the median survival times being 372 compared with 259 days. However, this survival difference was largely, although not entirely, accounted for by differences in performance status and response to induction chemotherapy between the two series. Moreover, in the 32 patients with limited disease, survival was longer in the no maintenance series, although this difference was not statistically significant.
A third study (Harper et al., 1987) reports on a total of 610 evaluable patients with limited or extensive disease initially. They were randomly assigned to eight or four courses of cyclophosphamide, vincristine and etoposide and there was a second randomisation to further chemotherapy with doxorubicin and methotrexate or to symptomatic treatment alone at the time of relapse. There was a small benefit from more prolonged chemotherapy, the median survival times being 39 and 32 weeks (P = 0.085), and the relapsefree intervals 31 and 23 weeks (P < 0.0002). However, when chemotherapy on relapse was given, the difference was eliminated. These three studies, together with the one currently reported, do show some evidence of benefit to be gained from prolonging treatment beyond a short induction period in some patients. Other studies using different drugs in the induction and maintenance phases have not shown any appreciable benefit (Woods et al., 1984; Feld et al., 1981 Feld et al., , 1984 . The question remains as to whether any advantage at all would be seen following more effective short-term regimens initially or on relapse. End-points must not only include short-term survival as expressed by median survival times, but proportions of long-term survivors at 2 and 3 years as in the present study.
The quality of survival is also important. In the present study, potentially troublesome adverse effects were reported in 61% of the patients during maintenance chemotherapy compared with only 12% during the same period in those who were allocated to no further chemotherapy until relapse (P < 0.0001), the main types being nausea, vomiting, paraes-thesia, peripheral neuropathy and mouth ulcers. Thus, patients can be spared a considerable amount of unpleasant and potentially serious toxicity if the policy is to give no more than six courses of chemotherapy in primary treatment.
The quality of life of the patients was also recorded intermittently by the clinicians and daily by the patients using a diary card during the-period of maintenance or no maintenance chemotherapy. According to both the clinicians' assessments, based on overall condition, level of physical activity and degree of breathlessness, and the patients' assessments, based on the severity of nausea and vomiting, level of physical activity, mood, degree of anxiety and overall condition, the quality of life was better for patients allocated not to receive maintenance chemotherapy.
In conclusion, no clear evidence has emerged from this study that survival can be prolonged to a clinically worthwhile extent by a policy of continuing chemotherapy beyond an initial six courses. Also, continuing chemotherapy beyond six courses increases the amount of unpleasant and potentially serious toxicity and adversely affects the quality of patients' lives. In view of the somewhat equivocal findings in the subgroup of patients who had a complete response to their initial chemotherapy, and the findings by Cullen et al. (1986) and Harper et al. (1987) that maintenance chemotherapy prolonged survival in some groups of patients, further studies on the optimum duration of chemotherapy in the treatment on small-lung cancer are required. The MRC Lung Cancer Working Party is currently comparing six versus three courses of the regimen used in the study reported here.
